Evaluating and treating small cell lung cancer

SCLC accounts for less than 15% of newly diagnosed lung cancers and can be distinguished from NSCLC by a high cell turnover rate and a rapidly progressive disease course, with a median survival of 3 months without treatment in extensive disease

by Dr Alexandra Leary and Dr Mary O'Brien
Coloured X-ray of the chest of a patient with SCLC (Photograph: PR M Brauner/SPL)
Coloured X-ray of the chest of a patient with SCLC (Photograph: PR M Brauner/SPL)

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package